Comparison of Ultrasound Guided Versus Blind Corticosteroid Injection for Trochanteric Bursitis

Bursitis Clinical Trial

Official title:

Prospective, Randomized Trial of Ultrasound Guided and Blind Corticosteroid Injection for Trochanteric Bursitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02221817
• Other study ID #: 1407358564
• Status: Completed
• Phase: N/A
• Start date: August 2014
• Est. completion date: April 2015

Study information

• Verified date: September 2021
• Source: West Virginia University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Trochanteric bursitis is a common condition, effecting 20% of the population. \Most with trochanteric bursitis experience chronic intermittent or continuous hip pain at and around the greater trochanter. The cause of trochanteric bursitis is believed to be a result of inflammation of the bursa, though this has not been confirmed. Accordingly, the use of corticosteroid injections has been shown to provide considerable relief. However, routine "blind" injections, those performed without the aid of imaging, such as fluoroscopy, have shown limited success in the appropriate needle placement. Fortunately, blind injections have yielded positive results in majority of the cases. Additionally, the use of fluoroscopy has not shown to improve clinical outcome for trochanter bursa injections. Although the use of fluoroscopy has not shown positive benefit, other modes of imaging, such as ultrasound have not been studied and may be more useful. Fluoroscopy allows for bony-landmark based injections. Ultrasound allows for direct visualization of the soft tissue structures such as the bursa and has gained significant support for use in musculoskeletal injections. This prospective blinded study's aim is to evaluate, if any, the benefit of an ultrasound guided injection and whether ultrasound should be routinely used during trochanter bursa injections.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: April 2015
• Est. primary completion date: April 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

1. Clinical diagnosis of trochanteric bursitis

2. 18 years of age or older when written informed consent is obtained

3. Signed Institutional Review Board (IRB) approved informed consent form

Exclusion Criteria:

1. Allergy to triamcinolone or bupivicaine

2. Coagulopathy

3. Active Infection

4. Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or complete study assessments

Related Conditions & MeSH terms

• Bursitis

Intervention

Procedure:
• Trochanter bursa injections

Device:
• Ultrasound

Locations

Country	Name	City	State
United States	West Virginia University Hospitals	Morgantown	West Virginia

Sponsors (1)

Lead Sponsor	Collaborator
West Virginia University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pain Intensity Measured on Visual Analog Scale (VAS)		3 month
Secondary	Disability Measured on Becks Disability Scale		Baseline, 2 weeks, 3 month
Secondary	Adverse Effects		2 weeks, 3 month
Secondary	Pain Improvement	Percent improvement	2 weeks, 3 months